Conference Presentation

Organon to show pooled ADORING data on VTAMA in AD across pediatric, adult ages

The July 22 presentation recasts already-approved Phase 3 results by age subgroup rather than adding a new clinical readout for the AhR agonist cream.

By AppliedXLJuly 14, 2026Trial NCT05032859

Executive Summary

Organon will present a pooled analysis of its two pivotal atopic dermatitis trials at a pediatric dermatology meeting, breaking results out by age group rather than presenting new data.
The underlying trials completed years ago and their results, including the primary endpoint outcome, have already been public and already support the drug's approved atopic dermatitis label.
The venue and framing point toward reinforcing prescriber comfort in younger pediatric patients rather than changing the regulatory or competitive picture.
No rival aryl hydrocarbon receptor agonist is active in atopic dermatitis, so this presentation does not respond to competitive pressure on the mechanism.

The presentation

Organon (NYSE: OGN) will present a pooled post hoc analysis of Phase 3 ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859) data on VTAMA cream in atopic dermatitis at the 2026 Society for Pediatric Dermatology Annual Meeting, held July 22-25, 2026, in Minneapolis. The abstract, titled 'Tapinarof 1% Cream in Atopic Dermatitis: Consistent Efficacy Across Age Groups From Pooled ADORING Trials,' is scheduled for an oral session on July 23. The analysis pools data from two 8-week pivotal trials to examine efficacy and safety across pediatric and adult age subgroups. Organon

Probability of Success

Endpoint Met96%

Completes99%

Clinical Significance56%

Regulatory98%

The underlying trial

NCT05032859, the ADORING 2 trial, enrolled 406 patients ages 2 and older with moderate to severe atopic dermatitis, randomizing them to tapinarof cream or vehicle cream once daily. The trial completed in February 2023 and its primary endpoint measured the percentage of subjects reaching a validated Investigator Global Assessment score of clear or almost clear with at least a 2-grade improvement from baseline to Week 8. Results were first posted to the registry in September 2025. The pooled ADORING 1 and 2 analysis, as reported in Organon's release, showed a Week 8 vIGA-AD response of 45.9% for tapinarof versus 15.9% for vehicle, with separation from vehicle beginning at Week 1 and improvements on EASI75 and itch measures. NCT05032859+1

Already approved

VTAMA cream carries an atopic dermatitis indication for adults and pediatric patients 2 years and older, alongside its existing plaque psoriasis indication in adults. The American Academy of Dermatology has issued recommendations for VTAMA's use in atopic dermatitis in that same population. That approval history means the July presentation functions as post-approval evidence communication aimed at pediatric dermatologists, rather than a pending regulatory catalyst. Organon

The competitive field

No other AhR agonist is active in atopic dermatitis: the closest direct comparator sharing tapinarof's target and modality is Organon's own follow-on tapinarof trial, NCT07265479. The atopic dermatitis field itself is populated mostly by JAK inhibitors and biologics with different mechanisms, including upadacitinib, abrocitinib, and amlitelimab, none of which share tapinarof's AhR-agonist mechanism. That structure means the pooled analysis has no direct rival readout to respond to; its relevance sits in reinforcing tapinarof's place among small-molecule topical options rather than repositioning it against a competing mechanism.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.